Clinical Trials Logo

Advanced or Metastatic NSCLC clinical trials

View clinical trials related to Advanced or Metastatic NSCLC.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05435248 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Start date: March 2, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

HS-10375 is an oral, highly selective, small molecular inhibitor of EGFR C797S. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10375 in Chinese advanced or metastatic NSCLC.

NCT ID: NCT04612751 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

TROPION-Lung04
Start date: February 2, 2021
Phase: Phase 1
Study type: Interventional

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

NCT ID: NCT03673332 Recruiting - Clinical trials for Advanced or Metastatic NSCLC

Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

EPITOP-01
Start date: August 9, 2019
Phase: Phase 4
Study type: Interventional

The co-primary objectives will be to assess the safety and quality of life under treatment.